DE69730516D1 - 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten - Google Patents

2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten

Info

Publication number
DE69730516D1
DE69730516D1 DE69730516T DE69730516T DE69730516D1 DE 69730516 D1 DE69730516 D1 DE 69730516D1 DE 69730516 T DE69730516 T DE 69730516T DE 69730516 T DE69730516 T DE 69730516T DE 69730516 D1 DE69730516 D1 DE 69730516D1
Authority
DE
Germany
Prior art keywords
imidazolinylaminoindol
alpha
compounds
adrenoceptor agonists
adrenoceptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730516T
Other languages
English (en)
Other versions
DE69730516T2 (de
Inventor
Todd Henry
James Sheldon
Lee Seibel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE69730516D1 publication Critical patent/DE69730516D1/de
Application granted granted Critical
Publication of DE69730516T2 publication Critical patent/DE69730516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69730516T 1996-11-25 1997-11-21 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten Expired - Lifetime DE69730516T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3177796P 1996-11-25 1996-11-25
US31777P 1996-11-25
PCT/US1997/020801 WO1998023610A1 (en) 1996-11-25 1997-11-21 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists

Publications (2)

Publication Number Publication Date
DE69730516D1 true DE69730516D1 (de) 2004-10-07
DE69730516T2 DE69730516T2 (de) 2005-09-01

Family

ID=21861336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730516T Expired - Lifetime DE69730516T2 (de) 1996-11-25 1997-11-21 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten

Country Status (23)

Country Link
US (2) US6162818A (de)
EP (1) EP0944621B1 (de)
JP (1) JP2001506981A (de)
KR (1) KR100395356B1 (de)
CN (1) CN1092652C (de)
AR (1) AR013875A1 (de)
AT (1) ATE275142T1 (de)
AU (1) AU735767B2 (de)
BR (1) BR9713542A (de)
CA (1) CA2271841C (de)
CO (1) CO4910149A1 (de)
CZ (1) CZ180599A3 (de)
DE (1) DE69730516T2 (de)
ES (1) ES2225998T3 (de)
HU (1) HUP9904215A3 (de)
ID (1) ID22812A (de)
IL (1) IL130024A (de)
NO (1) NO992470L (de)
PE (1) PE16299A1 (de)
SK (1) SK68399A3 (de)
TR (1) TR199901885T2 (de)
WO (1) WO1998023610A1 (de)
ZA (1) ZA9710577B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
TR199901885T2 (xx) * 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
AU2042301A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited 1-aminoalkyl-1H-indoles for treating glaucoma
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
NZ537200A (en) * 2002-06-24 2007-09-28 Schering Corp Indole piperidine derivatives useful as histamine H3 antagonists
KR20050072812A (ko) 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100029662A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
TR199901885T2 (xx) * 1996-11-25 1999-10-21 The Procter & Gamble Company Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.

Also Published As

Publication number Publication date
HUP9904215A3 (en) 2002-01-28
EP0944621A1 (de) 1999-09-29
ID22812A (id) 1999-12-09
NO992470L (no) 1999-07-26
ES2225998T3 (es) 2005-03-16
US6395764B1 (en) 2002-05-28
TR199901885T2 (xx) 1999-10-21
IL130024A (en) 2002-12-01
CN1092652C (zh) 2002-10-16
KR20000069088A (ko) 2000-11-25
ATE275142T1 (de) 2004-09-15
US6162818A (en) 2000-12-19
IL130024A0 (en) 2000-02-29
JP2001506981A (ja) 2001-05-29
AU735767B2 (en) 2001-07-12
AR013875A1 (es) 2001-01-31
AU5438098A (en) 1998-06-22
CO4910149A1 (es) 2000-04-24
DE69730516T2 (de) 2005-09-01
CN1238771A (zh) 1999-12-15
EP0944621B1 (de) 2004-09-01
HUP9904215A2 (hu) 2000-06-28
SK68399A3 (en) 2000-07-11
CA2271841C (en) 2003-07-08
NO992470D0 (no) 1999-05-21
KR100395356B1 (ko) 2003-08-21
WO1998023610A1 (en) 1998-06-04
CA2271841A1 (en) 1998-06-04
PE16299A1 (es) 1999-03-12
ZA9710577B (en) 1998-06-25
CZ180599A3 (cs) 1999-11-17
BR9713542A (pt) 2000-01-25

Similar Documents

Publication Publication Date Title
ATE275142T1 (de) 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
DE69732244D1 (de) Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
ATE298739T1 (de) Calcylitische verbindungen
DE69624115T2 (de) Benzimidazol verbindungen
BR9709230A (pt) Composto
DE69616817T2 (de) Substituierte benzylaminopiperloin verbindungen
BR9707786B1 (pt) composto.
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
ITTO941090A0 (it) Dispositivo di freno per motoveicoli.
ITBO940102A0 (it) Perfezionamento ad un dispositivo adattatore per elettrocateteri.
DK0839989T3 (da) Udløselig forbindelse
DE69807397D1 (de) Triazinylaminostilben Verbindungen
DE69914594D1 (de) Aryl-annellierte azapolycyclische verbindungen
DE69939378D1 (de) Antithrombotische verbindungen
ID17723A (id) Senyawa untuk pengobatan
ZA9710579B (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists.
ATE225364T1 (de) Bromotiacumicin verbindungen
DE69719068T2 (de) Guanidinylamino-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
ZA9710574B (en) 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists.
IL132384A0 (en) 5-(2-Imidazolinylamino) benzimidazole compounds useful as alpha - 2 adrenoceptor agonists
HUP9904660A3 (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
FI4330U1 (fi) Höyläpenkki
ITBO940414A0 (it) Manipolo endoorale per riprese di video-immagini.
KR970049218U (ko) 탑재용 가이드 피스
IT242404Y1 (it) Dispositivo di semiapertura per infissi metallici.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA